PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot (PROSPER)
Postpartum Prophylaxis for PE Randomized Control Trial Pilot: A Pilot Study Assessing Feasibility of a Randomized, Open-label Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism
研究概览
详细说明
The PROPSER pilot is a randomized, open-label pilot study comparing prophylactic low molecular weight heparin (LMWH) to saline placebo. The PROSPER pilot study will assess the feasibility of conducting a full trial as measured by the number of subjects recruited per center per month. In addition, clinical data will be collected to determine an estimate of the primary outcome event rate (symptomatic VTE or asymptomatic proximal deep vein thrombosis (DVT) and major bleeding event rate for the full trial in LMWH and control groups. If our pilot results indicate that no substantial changes are needed to the study design, we will include the pilot data in the primary and secondary outcome analyses for the full trial (i.e. a "Vanguard trial" or internal pilot trial).
Eligible consenting women at risk of postpartum thrombosis will be randomized within 36 hours after delivery of the placenta and will be equally allocated to 2 trial arms, either the treatment group: prophylactic-dose LMWH, subcutaneously once daily for 10 days (+/-3 days), or the control group.
At 10 days (+/- 3 days), all women will have a study visit to assess for study outcomes, including bilateral leg ultrasound screening for VTE and a D-dimer test. A final telephone follow-up will occur at 90 days for outcome assessment of subsequent VTE, bleeding or other adverse events.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Alberta
-
Edmonton、Alberta、加拿大
- Royal Alexandra Hospital
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8N 3Z5
- McMaster University Medical Centre
-
Ottawa、Ontario、加拿大、K1H 8L6
- Ottawa Hospital General Campus & Civic Campus
-
Toronto、Ontario、加拿大
- SunnyBrook Health Sciences Centre
-
-
Quebec
-
Montreal、Quebec、加拿大
- SMBD Jewish General Hospital
-
-
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- University of Virginia Medical Center
-
-
Washington
-
Seattle、Washington、美国、98104
- Puget Sound Blood Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Women must be at high risk for thromboembolism for one of the following reasons:
- Known low risk thrombophilia (Known = diagnosed prior to enrollment and low risk thrombophilia includes heterozygous factor V Leiden or prothrombin gene variant or protein C deficiency or protein S deficiency. If not previously tested then assumed not to have thrombophilia).
- Immobilization (defined as >90% of waking hours in bed, of a week or more at any point in the antepartum period).
OR any two of the following reasons:
- Postpartum infection (fever (temperature>38.5oC) and clinical signs/symptoms of infection and elevated neutrophil count (higher than local lab normal))
- Postpartum hemorrhage (Estimated blood loss >1000 ml during delivery and postpartum)
- Pre-pregnancy BMI >25 kg/m2
- Emergency cesarean birth (emergency = not planned prior to onset of labour)
- Smoking >5 cigarettes per day prior to pregnancy
- Preeclampsia (blood pressure ≥ 140mmHG systolic and/or ≥90 mmHg diastolic on at least one occasion and proteinuria (1+ on urine dipstick or 300mg/dl or total excretion of 300mg/24 hours) or typical end-organ dysfunction.
- Infant birth weight (adjusted for sex and gestational age) <3rd percentile (i.e., small for gestational age).
Exclusion Criteria:
- Less than 6 hours or more than 36 hours since delivery at the time of randomization
Need for anticoagulation as judged by the local investigator, may include but not limited to:
- Personal history of previous provoked or unprovoked VTE (DVT or PE)
- Continuation of LMWH that was started in the antenatal period for VTE prophylaxis
- Mechanical heart valve
- Known high-risk thrombophilia (Known = diagnosed prior to enrolment and high-risk thrombophilia includes deficiency of antithrombin (at least 1 abnormal lab result), persistently positive anticardiolipin antibodies (> 30U/ml on two measurements a minimum of six weeks apart), persistently positive Anti B2 glycoprotein antibodies (> 20U/ml on two measurements a minimum of six weeks apart), persistently positive lupus anticoagulant (positive on two measurements a minimum of six weeks apart), homozygous factor V Leiden (FVL), homozygous prothrombin gene mutation (PGM), compound heterozygosity factor V Leiden (FVL) and prothrombin gene mutations (PGM), more than 1 thrombophilia (any combination of 2 or more: FVL, PGM, protein C deficiency, protein S deficiency). If not previously tested then assumed not to have thrombophilia).
Contraindication to heparin therapy, including:
- History of heparin induced thrombocytopenia (HIT)
- Platelet count of less than 80,000 x 106/L on postpartum Complete Blood Count(CBC)
- Hemoglobin ≤ 75 g/L on postpartum CBC
- Active bleeding at any site (not resolved prior to randomization)
- Excessive postpartum vaginal bleeding (>1 pad per hour prior to randomization).
- Documented gastrointestinal ulcer within 6 weeks prior to randomization
- History of heparin or LMWH allergy
- Severe postpartum hypertension (systolic blood pressure (SBP) > 200mm/hg and/or diastolic blood pressure (DBP) > 120mm/hg)
- Severe hepatic failure (INR >1.8 if liver disease suspected)
- Have received more than one dose of heparin or LMWH since delivery
- < age of legal majority in local jurisdiction (age <18 in Canada)
- Prior participation in PROSPER
- Unable or refused to consent
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:low molecular weight heparin
Prophylactic-dose (5000 IU/0.2ml)low molecular weight heparin (LMWH), administered subcutaneously once daily in pre-filled glass syringes for 10 days (+/- 3 days) for a total of 10 (+/-3) study drug injections.
|
5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
其他名称:
|
无干预:Control Group
No treatment control group.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Feasibility of Recruitment and Trial Operations.
大体时间:4 months
|
The average number of subjects that are recruited per site per month during a 4 month active recruitment phase at each site.
|
4 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Venous Thromboembolism in the Early Postpartum Period.
大体时间:From randomization to Day 10
|
This includes symptomatic Deep Vein Thrombosis (DVT) or pulmonary embolism (PE) in the interval between randomization and the last dose of study drug (10 days +/- 3 days) OR asymptomatic proximal DVT detected by compression ultrasound of both legs done within 24hrs of the last dose of study drug (10 days (+/- 3 days) postpartum).
Compressed and non-compressed images will be obtained from the calf trifurcation to the inguinal ligament.
All suspected outcomes will be adjudicated by a blinded expert adjudication committee.
|
From randomization to Day 10
|
Late Symptomatic Venous Thromboembolism
大体时间:From Day 10 to Day 90
|
This includes symptomatic Deep Vein Thrombosis or Pulmonary Embolism.
Suspected outcomes will be adjudicated by a blinded adjudication committee.
|
From Day 10 to Day 90
|
Death From Venous Thromboembolism
大体时间:From Randomization to Day 90
|
If a subject dies between randomization and late postpartum follow up (Day 90 +/- 7 days) the death will be adjudicated as certain, highly probable, probable, or unlikely due to Pulmonary Embolism (PE) using the following criteria. Certain: hypotension, hypoxia, cardiac arrest with no other explanation other than PE and autopsy or radiographic confirmation Highly probable: criteria for certain but another disease could have caused the death Probable: other cause suspected based on clinical evidence but 100% certainty not available Unlikely: all other cases. |
From Randomization to Day 90
|
Major Bleeding or Clinically Relevant Non-major Bleeding
大体时间:From Randomization to Day 90
|
Major bleeding meets at least one of the following: Fatal bleeding; Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, retroperitoneal, etc.); Bleeding causing a fall in hemoglobin level of 20 g L-1 (1.24 mmol L-1) or more, or leading to transfusion of two or more units of whole blood or red cells . Clinically Relevant Non-major Bleeding does not meet the criteria for major bleeding but meets at least one of the following: Hospitalization; Medical intervention; Unscheduled contact with a physician; Discomfort (pain, or impairment of activities of daily life). |
From Randomization to Day 90
|
Heparin Induced Thrombocytopenia
大体时间:From Randomization to Day 90
|
All subjects who develop thrombocytopenia (platelets less than 80 x 109/L and/or with >50% decrease from baseline) will be investigated for Heparin Induced Thrombocytopenia (HIT) by having ELISA and serotonin release assays to confirm or refute a diagnosis of HIT.
HIT will be diagnosed with a positive PF4 (platelet factor 4) HIT ELISA assay.
|
From Randomization to Day 90
|
合作者和调查者
调查人员
- 首席研究员:Marc A Rodger, M.D., MSc.、Ottawa Hospital Research Institute
出版物和有用的链接
一般刊物
- Middleton P, Shepherd E, Gomersall JC. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2021 Mar 29;3(3):CD001689. doi: 10.1002/14651858.CD001689.pub4.
- Rodger MA, Phillips P, Kahn SR, Bates S, McDonald S, Khurana R, James AH, Konkle BA; PROSPER Investigators: Tim Ramsay, Dean Fergusson, Anne McLeod, Wee Shian Chan, Rshmi Khurana, Kara Narenberg, Haim Abenhaim, John Heit, Ghada Bourjeilly, Paul Gibson, Kent Bailey. Low molecular weight heparin to prevent postpartum venous thromboembolism: A pilot study to assess the feasibility of a randomized, open-label trial. Thromb Res. 2016 Jun;142:17-20. doi: 10.1016/j.thromres.2016.04.004. Epub 2016 Apr 9. No abstract available.
- Rodger MA, Phillips P, Kahn SR, James AH, Konkle BA; PROSPER Investigators. Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thromb Haemost. 2015 Jan;113(1):212-6. doi: 10.1160/TH14-06-0485. Epub 2014 Nov 6.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Dalteparin Sodium的临床试验
-
Sanofi完全的静脉血栓栓塞症美国, 加拿大, 俄罗斯联邦, 乌克兰, 火鸡, 印度, 墨西哥, 埃及, 立陶宛, 哥伦比亚, 秘鲁, 大韩民国, 智利, 白俄罗斯, 中国, 南非
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)招聘中